{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:15:57Z","timestamp":1773249357441,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.idc.2012.08.004","type":"journal-article","created":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T22:00:57Z","timestamp":1347314457000},"page":"931-948","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era"],"prefix":"10.1016","volume":"26","author":[{"given":"Vincent","family":"Soriano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Labarga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Vispo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Vicente","family":"Fern\u00e1ndez-Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2012.08.004_bib1","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the HIV: the D: A:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.idc.2012.08.004_bib2","unstructured":"Ruppik M, Ledergerber B, Rickenbach M, et\u00a0al. Changing patterns of causes of\u00a0death: SCCS, 2005 to 2009. Presented at CROI, Boston (MA), February 27\u2013March 2, 2011 [abstract 789]."},{"key":"10.1016\/j.idc.2012.08.004_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cld.2010.09.012","article-title":"HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury","volume":"15","author":"Merwat","year":"2011","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.idc.2012.08.004_bib4","series-title":"Sherlock\u2019s diseases of the liver and biliary system","first-page":"438","article-title":"HIV and the liver","author":"Peters","year":"2011"},{"key":"10.1016\/j.idc.2012.08.004_bib5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2012.08.004_bib6","unstructured":"European AIDS Clinical Society (EACS) guidelines, October 2011. Available at: www.europeanaidsclinicalsociety.org. Accessed August 28, 2012."},{"key":"10.1016\/j.idc.2012.08.004_bib7","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2012.08.004_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/QAI.0b013e31803151c7","article-title":"Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV\/hepatitis C virus-coinfected patients","volume":"44","author":"Shafran","year":"2007","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2012.08.004_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2893.2009.01261.x","article-title":"Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance","volume":"18","author":"Blanco","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.idc.2012.08.004_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2012.08.004_bib11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","article-title":"Clinical syndromes and consequences of antiretroviral-related hepatotoxicity","volume":"52","author":"Nu\u00f1ez","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2012.08.004_bib12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients","volume":"196","author":"Labarga","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2012.08.004_bib13","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/QAD.0b013e328216f2c7","article-title":"Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection","volume":"21","author":"Dore","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2012.08.004_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2893.2010.01309.x","article-title":"HCV treatment uptake and changes in the prevalence of HCV genotypes in HIV\/HCV-coinfected patients","volume":"18","author":"Medrano","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.idc.2012.08.004_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3851\/IMP1992","article-title":"Predicted effect of direct acting antivirals in the current HIV-HCV coinfected population in Spain","volume":"17","author":"Poveda","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idc.2012.08.004_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/aid.2005.21.599","article-title":"Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation?","volume":"21","author":"Maida","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.idc.2012.08.004_bib17","first-page":"190","article-title":"Liver and kidney transplantation in HIV-infected patients","volume":"11","author":"Tan-Tam","year":"2009","journal-title":"AIDS Rev"},{"key":"10.1016\/j.idc.2012.08.004_bib18","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2012.08.004_bib19","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2012.08.004_bib20","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2012.08.004_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","article-title":"Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or 2b to patients with chronic hepatitis C","volume":"140","author":"Marcellin","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2012.08.004_bib22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2012.08.004_bib23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2012.08.004_bib24","doi-asserted-by":"crossref","unstructured":"Lenz O, Fevery B, Vijgen L, et\u00a0al. TMC-435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon\/ribavirin treatment: virological analyses of the ASPIRE trial. Presented at 47th EASL, Barcelona, April 18\u201322, 2012 [abstract 9].","DOI":"10.1016\/S0168-8278(12)60023-3"},{"key":"10.1016\/j.idc.2012.08.004_bib25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1053\/j.gastro.2011.12.057","article-title":"Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C","volume":"142","author":"Chu","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2012.08.004_bib26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkq086","article-title":"New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals","volume":"65","author":"Seden","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2012.08.004_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/17425255.2011.558839","article-title":"Approaches for understanding and predicting drug interactions in HIV-infected patients","volume":"7","author":"Jim\u00e9nez-N\u00e1cher","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.idc.2012.08.004_bib28","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/QAD.0b013e32834bbb90","article-title":"Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients","volume":"25","author":"Soriano","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2012.08.004_bib29","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV\/hepatitis C virus-coinfected patients","volume":"24","author":"Rall\u00f3n","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2012.08.004_bib30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiq098","article-title":"Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C","volume":"203","author":"Nattermann","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2012.08.004_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QAI.0b013e318186ede8","article-title":"Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV\/HCV-coinfected patients","volume":"50","author":"Ryan","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2012.08.004_bib32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3851\/IMP1298","article-title":"Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study","volume":"14","author":"Cacoub","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idc.2012.08.004_bib33","unstructured":"Dieterich D, Soriano V, Sherman K, et\u00a0al. Telaprevir in combination with peginterferon \u03b1-2a plus ribavirin for HIV\/HCV coinfected patients: SVR12 interim analysis. Presented at 19th CROI. Seattle (WA), March 5\u20138, 2012 [abstract 56]."},{"key":"10.1016\/j.idc.2012.08.004_bib34","doi-asserted-by":"crossref","unstructured":"Mallolas J, Pol S, Rivero A, et\u00a0al. Boceprevir plus peginterferon\/ribavirin for the treatment of HIV-HCV coinfected patients: end of treatment week 48 interim results. Presented at 47th EASL Barcelona, April 18\u201322, 2012 [abstract 366].","DOI":"10.1016\/S0168-8278(12)60064-6"},{"key":"10.1016\/j.idc.2012.08.004_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkn175","article-title":"Why different dynamics of selection of drug resistance in HIV, hepatitis B and C viruses?","volume":"62","author":"Soriano","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2012.08.004_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/QAI.0b013e3181a02fda","article-title":"Detection of hepatitis C mutants with natural resistance to NS3\/4A protease inhibitors in HIV\/HCV-coinfected individuals treated with antiretroviral therapy","volume":"51","author":"Morsica","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2012.08.004_bib37","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/jac\/dkr385","article-title":"Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV-HCV coinfected patients","volume":"66","author":"Plaza","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2012.08.004_bib38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.antiviral.2009.10.021","article-title":"Viral hepatitis and HIV co-infection","volume":"85","author":"Soriano","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.idc.2012.08.004_bib39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2012.08.004_bib40","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrhosis during interferon-based therapy","volume":"38","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2012.08.004_bib41","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM200210173471623","article-title":"Weight loss in HIV-infected patients","volume":"347","author":"Garcia-Benayas","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2012.08.004_bib42","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1086\/383151","article-title":"Nucleoside analogues and mitochondrial toxicity","volume":"38","author":"Fleischer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2012.08.004_bib43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","article-title":"Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir","volume":"13","author":"Vispo","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idc.2012.08.004_bib44","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jac\/dkn420","article-title":"Efficacy of pegylated interferon plus ribavirin treatment in HIV\/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone","volume":"62","author":"Mira","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2012.08.004_bib45","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1097\/QAD.0b013e3283177f38","article-title":"Increase in serum bilirubin in HIV\/hepatitis C virus-coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin","volume":"22","author":"Rodr\u00edguez-N\u00f3voa","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2012.08.004_bib46","unstructured":"Van Heeswijk R, Vandervoorde A, Boogaerts G, et\u00a0al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at 18th CROI. Boston (MA), February 27\u2013March 2, 2011 [abstract 119]."},{"key":"10.1016\/j.idc.2012.08.004_bib47","unstructured":"Van Heeswijk R, Gysen V, Boogaerts G, et\u00a0al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir. Presented at 48th ICAAC. Washington (DC), October 25\u201328, 2008. p. A-966."},{"key":"10.1016\/j.idc.2012.08.004_bib48","unstructured":"Van Heeswijk R, Boogaerts G, de Paepe E, et\u00a0al. The pharmacokinetic interaction between escitalopram or esomeprazole and telaprevir. Presented at 15th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Boston (MA), June 23\u201324, 2010 [abstract 76]."},{"issue":"Suppl","key":"10.1016\/j.idc.2012.08.004_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0168-8278(11)61246-4","article-title":"The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. EASL, Berlin, Germany; March 30-April 3, 2011","volume":"54","author":"Van Heeswijk","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.idc.2012.08.004_bib50","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","article-title":"Characterisation of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.idc.2012.08.004_bib51","unstructured":"Kasserra C, Hughes E, Treitel M, et\u00a0al. Clinical pharmacology of BOC: metabolism, excretion and drug-drug interactions. Presented at 18th CROI. Boston (MA), February 27\u2013March 2, 2011 [abstract 118]."},{"key":"10.1016\/j.idc.2012.08.004_bib52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.idc.2012.08.004_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.idc.2012.08.004_bib54","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","article-title":"Second-phase HCV RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration","volume":"53","author":"Guedj","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2012.08.004_bib55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.idc.2012.08.004_bib56","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jac\/dkr215","article-title":"Directly acting antivirals against hepatitis C virus","volume":"66","author":"Soriano","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2012.08.004_bib57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkp388","article-title":"Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)","volume":"65","author":"Kieffer","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2012.08.004_bib58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3851\/IMP1760","article-title":"Natural polymorphisms associated with resistance to new antivirals against hepatitis C virus (HCV) in newly diagnosed HIV\/HCV-coinfected patients in Spain","volume":"16","author":"Trevi\u00f1o","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idc.2012.08.004_bib59","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1468-1293.2011.00913.x","article-title":"HCV protease variability and anti-HCV protease inhibitor resistance in HIV\/HCV-coinfected patients","volume":"12","author":"Trimoulet","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.idc.2012.08.004_bib60","unstructured":"Miro JM, Castells L, Valdivieso A, et\u00a0al. Treatment with pegIFN+RBV of 67 HIV+ patients with recurrent HCV infection after liver transplantation. Presented at CROI 2011. Boston (MA), February 27\u2013March 2, 2011 [abstract 964]."},{"key":"10.1016\/j.idc.2012.08.004_bib61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2012.08.004_bib62","unstructured":"Soriano V. A new era for hepatitis C \u2013 new diagnostic tools and new weapons. ACS Med Chem Lett, in press."}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552012000803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552012000803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T03:17:03Z","timestamp":1714360623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552012000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0891552012000803"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2012.08.004","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}